161 related articles for article (PubMed ID: 28817390)
1. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
Palavalli Parsons LH; Roane B; Manders DB; Richardson DL; Kehoe SM; Carlson M; Miller DS; Lea JS
Am J Clin Oncol; 2018 Oct; 41(10):933-937. PubMed ID: 28817390
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
3. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity.
Manders DB; Kehoe SM; Miller DS; Lea JS; Richardson DL
Am J Clin Oncol; 2018 Aug; 41(8):797-801. PubMed ID: 28225444
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Monk BJ; Sill MW; Burger RA; Gray HJ; Buekers TE; Roman LD
J Clin Oncol; 2009 Mar; 27(7):1069-74. PubMed ID: 19139430
[TBL] [Abstract][Full Text] [Related]
7. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
8. Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
Xiao Y; Cheng HJ; Wang L; Luo SX
Eur J Gynaecol Oncol; 2017; 38(1):76-79. PubMed ID: 29767869
[TBL] [Abstract][Full Text] [Related]
9. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
11. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
[TBL] [Abstract][Full Text] [Related]
13. A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
Tognarelli A; Faggioni L; Manassero F; Gadducci A; Selli C
BMC Urol; 2019 Dec; 19(1):128. PubMed ID: 31818277
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
[TBL] [Abstract][Full Text] [Related]
15. Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy.
Sturdza A; Hofmann S; Kranawetter M; Polterauer S; Grimm C; Krainer M; Kirisits C; Pötter R; Reinthaller A; Schwameis R
Strahlenther Onkol; 2017 Dec; 193(12):1056-1065. PubMed ID: 28721510
[TBL] [Abstract][Full Text] [Related]
16. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.
Monk BJ; Han E; Josephs-Cowan CA; Pugmire G; Burger RA
Gynecol Oncol; 2006 Aug; 102(2):140-4. PubMed ID: 16790264
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
Machida H; Moeini A; Ciccone MA; Mostofizadeh S; Takiuchi T; Brunette LL; Roman LD; Matsuo K
Am J Clin Oncol; 2018 Sep; 41(9):851-860. PubMed ID: 28763329
[TBL] [Abstract][Full Text] [Related]
18. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
20. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]